AU2001272491A1 - Triple fusion proteins comprising ubiquitin fused between thioredoxin and a polypeptide of interest - Google Patents

Triple fusion proteins comprising ubiquitin fused between thioredoxin and a polypeptide of interest

Info

Publication number
AU2001272491A1
AU2001272491A1 AU2001272491A AU7249101A AU2001272491A1 AU 2001272491 A1 AU2001272491 A1 AU 2001272491A1 AU 2001272491 A AU2001272491 A AU 2001272491A AU 7249101 A AU7249101 A AU 7249101A AU 2001272491 A1 AU2001272491 A1 AU 2001272491A1
Authority
AU
Australia
Prior art keywords
thioredoxin
polypeptide
interest
fusion proteins
triple fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001272491A
Inventor
Teresa Elisa Virginia Cabezon-Silva
Anne-Marie Eva Fernande Delisse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
SmithKline Beecham Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0015619A external-priority patent/GB0015619D0/en
Priority claimed from GB0026484A external-priority patent/GB0026484D0/en
Application filed by SmithKline Beecham Biologicals SA filed Critical SmithKline Beecham Biologicals SA
Publication of AU2001272491A1 publication Critical patent/AU2001272491A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
AU2001272491A 2000-06-26 2001-06-19 Triple fusion proteins comprising ubiquitin fused between thioredoxin and a polypeptide of interest Abandoned AU2001272491A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0015619A GB0015619D0 (en) 2000-06-26 2000-06-26 Novel method
GB0015619 2000-06-26
GB0026484A GB0026484D0 (en) 2000-10-30 2000-10-30 Novel system
GB0026484 2000-10-30
PCT/EP2001/006952 WO2002000892A1 (en) 2000-06-26 2001-06-19 Triple fusion proteins comprising ubiquitin fused between thioredoxin and a polypeptide of interest

Publications (1)

Publication Number Publication Date
AU2001272491A1 true AU2001272491A1 (en) 2002-01-08

Family

ID=26244545

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001272491A Abandoned AU2001272491A1 (en) 2000-06-26 2001-06-19 Triple fusion proteins comprising ubiquitin fused between thioredoxin and a polypeptide of interest

Country Status (6)

Country Link
US (1) US20030104570A1 (en)
EP (1) EP1294905A1 (en)
JP (1) JP2004501648A (en)
AU (1) AU2001272491A1 (en)
CA (1) CA2412084A1 (en)
WO (1) WO2002000892A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003010204A1 (en) * 2001-07-26 2003-02-06 Advanced Protein Technologies Corp. Process for preparation of polypeptides of interest from fusion peolypeptides
WO2005026375A2 (en) 2003-05-22 2005-03-24 Fraunhofer Usa, Inc. Recombinant carrier molecule for expression, delivery and purification of target polypeptides
TWI305230B (en) * 2004-06-25 2009-01-11 Univ Feng Chia Nucleic acid construct and expression vector for enhancing the production of recombinant protein, and method for the massive production of recombinant protein
EP1853305B1 (en) * 2005-02-04 2014-08-20 Survac ApS Survivin peptide vaccine
WO2007117264A2 (en) 2005-08-03 2007-10-18 Fraunhofer Usa, Inc. Compositions and methods for production of immunoglobulins
WO2007095320A2 (en) * 2006-02-13 2007-08-23 Fraunhofer Usa, Inc. Hpv antigens, vaccine compositions, and related methods
ES2709176T3 (en) 2006-08-11 2019-04-15 Life Sciences Res Partners Vzw Immunogenic peptides and their use in immune disorders
CA2692933C (en) 2007-07-11 2016-10-18 Fraunhofer Usa, Inc. Yersinia pestis antigens, vaccine compositions, and related methods
ES2650236T3 (en) 2008-02-14 2018-01-17 Life Sciences Research Partners Vzw CD4 + T lymphocytes with cytolytic properties
US20100330088A1 (en) * 2008-02-14 2010-12-30 Jean-Marie Saint-Remy Strategies to prevent and/or treat immunie responses to soluble allofactors
WO2009101208A2 (en) 2008-02-14 2009-08-20 Life Sciences Research Partners Vzw Immunotherapy targeting intracellular pathogens
AU2013270496B2 (en) * 2008-02-14 2016-02-04 Katholieke Universiteit Leuven Immunogenic control of tumours and tumour cells
CA2715488C (en) * 2008-02-14 2019-09-24 Life Sciences Research Partners Vzw Immunogenic control of tumours and tumour cells
ES2626115T3 (en) 2008-02-14 2017-07-24 Life Sciences Research Partners Vzw Immunogenic peptides and their use in transplantation
AU2009214038B2 (en) * 2008-02-14 2013-08-22 Katholieke Universiteit Leuven Elimination of immune responses to viral vectors
US8734803B2 (en) 2008-09-28 2014-05-27 Ibio Inc. Humanized neuraminidase antibody and methods of use thereof
WO2011041391A1 (en) 2009-09-29 2011-04-07 Fraunhofer Usa, Inc. Influenza hemagglutinin antibodies, compositions, and related methods
KR101643761B1 (en) * 2009-12-04 2016-07-29 삼성전자주식회사 Fusion protein comprising ubiquitin or ubiquitin-like protein, membrane transfer domain and biologically active molecule and uses thereof
EP2527434B1 (en) * 2010-01-22 2017-08-09 Japan Science and Technology Agency Probe reagent for measurement of proteolytic activity
RU2615460C2 (en) 2010-11-25 2017-04-04 Имнейт Сарл Immunogenic peptides for application for prevention and/or treatment of infectious diseases, autoimmune diseases, the immune responses to allogeneic factors, allergic diseases, tumour, transplant rejection and immune responses against viral vectors used for genetic therapy or genetic vaccination
GB201201511D0 (en) 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
US10729791B2 (en) 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
JP7090335B2 (en) 2015-09-25 2022-06-24 イムサイス エスエー Improved methods and compounds for eliminating the immune response to therapeutic agents
SG11201808710UA (en) 2016-04-19 2018-11-29 Imcyse Sa Novel immunogenic cd1d binding peptides

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2071315T3 (en) * 1990-05-09 1995-06-16 Massachusetts Inst Technology UBIQUITINE-SPECIFIC PROTEASE.
US5270181A (en) * 1991-02-06 1993-12-14 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin and thioredoxin-like molecules
US6235525B1 (en) * 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
US5585245A (en) * 1994-04-22 1996-12-17 California Institute Of Technology Ubiquitin-based split protein sensor
TR199902053T2 (en) * 1997-02-25 2000-04-21 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use.
GB9717953D0 (en) * 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine

Also Published As

Publication number Publication date
US20030104570A1 (en) 2003-06-05
CA2412084A1 (en) 2002-01-03
EP1294905A1 (en) 2003-03-26
WO2002000892A1 (en) 2002-01-03
JP2004501648A (en) 2004-01-22

Similar Documents

Publication Publication Date Title
AU2001272491A1 (en) Triple fusion proteins comprising ubiquitin fused between thioredoxin and a polypeptide of interest
AU2001266557A1 (en) Albumin fusion proteins
AU2002361642A1 (en) Recombinant antibody fusion proteins and methods for detection of apoptotic cells
WO1999066054A3 (en) Erythropoietin analog-human serum albumin fusion protein
AU2002214531A1 (en) Proteins and nucleic acids encoding same
AU7266898A (en) Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
AU7274898A (en) Recombinant antibody-enzyme fusion proteins
AU2001261499A1 (en) Methods of detecting interactions between proteins, peptides or libraries thereof using fusion proteins
AU2001291049A1 (en) Defensin-antigen fusion proteins
AU3562299A (en) Inhibin-hbc fusion protein
AU2002332041A1 (en) Albumin fusion proteins
AU9798398A (en) Gfp-annexin fusion proteins
AU2001288390A1 (en) Proteins and nucleic acids encoding same
WO2002072792A8 (en) Heterologous fusion protein constructs comprising a leishmania antigen
AU2002344219A1 (en) Fusion proteins of biologically active peptides and antibodies
AU1672499A (en) Proteinase inhibitor fusion proteins
WO2002094870A8 (en) Proteins and nucleic acids encoding same
AU2001239889A1 (en) Polypeptides and nucleic acids encoding same
AU1183200A (en) Novel gene encoding brain-specific membrane protein
AU2002322416A1 (en) Gfp fusion proteins and their use
AU2002365084A1 (en) Method and reagent for the detection of proteins and peptides
AU2001280993A1 (en) Tissue-associated proteins and their uses
AU2002211681A1 (en) Proteins and nucleic acids encoding same
AU2002213954A1 (en) Method for the selective modification of peptides and proteins
AU2002221380A1 (en) Adapter protein and gene encoding it